ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

VOLUNTARY ANNOUNCEMENT

UPDATES ON THE CLINICAL TRIAL OF IMM0306

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the "**Board**") of directors ("**Directors**", and each a "**Director**") of the Company is pleased to announce that a total of 27 evaluable patients (25 follicular lymphoma (FL) patients and two marginal zone lymphoma (MZL) patients) had been enrolled by October 26, 2024, for the Phase Ib/IIa clinical trial of IMM0306 in combination with lenalidomide for indolent lymphoma. The following diagram illustrates the efficacy data in patients with relapsed or refractory (R/R) FL as of October 26, 2024:

Best Response no. (%)	Phase Ib (N=9)	Phase IIa (N=16)	Total (N=25)
CR	3 (33.3)	7 (43.8)	10 (40.0)
PR	5 (55.6)	6 (37.5)	11 (44.0)
SD	0	1 (6.3)	1 (4.0)
PD	1 (11.1)	2 (12.5)	3 (12.0)
ORR	8 (88.9)	13 (81.3)	21 (84.0)

Note: The percentage figures have been subject to rounding adjustments.

Abbreviations: CR refers to complete response; PR refers to partial response; SD refers to stable disease; PD refers to progressive disease.

As of October 26, 2024, the overall response rate (ORR) and complete response rate (CRR) in 25 evaluable R/R FL patients were 84.0% and 40.0%, respectively, and for R/R MZL, the ORR achieved 100.0% in two evaluable patients, demonstrating an outstanding efficacy signal. The study is currently under active enrollment and observation.

ABOUT IMM0306

IMM0306, independently developed by the Group, is a bispecific molecule targeting both cluster of differentiation 47 (CD47) and cluster of differentiation 20 (CD20) and is the first CD47 and CD20 dual-targeting bispecific to enter into clinical stage globally. With enhanced antibody-dependent cellular phagocytosis (ADCP) activity and antibody-dependent cellular cytotoxicity (ADCC) activity, IMM0306 can simultaneously bind to CD47 and CD20 expressed on malignant B cells, with a higher affinity for CD20 than CD47, leading to improved therapeutic outcomes.

As of the date of this announcement, the Group owns the global intellectual property rights and commercial rights of IMM0306.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, IMM0306, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
Tian Wenzhi
Chairman and Executive Director

Shanghai, the PRC, November 18, 2024

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong as non-executive Director; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.